- Home
- GOSS
GOSS
Gossamer Bio Inc.
as 12-18-2024 4:00pm EST
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 212.9M | IPO Year: | 2019 |
| Target Price: | $9.20 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $1.60 | Next Earning Date: | 11-07-2024 |
| Revenue: | $105,322,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -81.17% |
Latest Gossamer Bio Inc. News
GOSS Breaking Stock News: Dive into GOSS Ticker-Specific Updates for Smart Investing
Simply Wall St.
16 days ago
US Penny Stocks: 3 Picks With Market Caps Under $200M
Zacks
a month ago
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy
Zacks
a month ago
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
Zacks
a month ago
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
Simply Wall St.
a month ago
Industry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue Forecasts
Business Wire
a month ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Gossamer Bio, Inc. (NASDAQ:GOSS) Just Reported And Analysts Have Been Lifting Their Price Targets
Zacks
a month ago
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
Compare GOSS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GOSS Gossamer Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.